ipragliflozin
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Despite the benefits of pioglitazone in the treatment of non-alcoholic fatty liver disease (NAFLD), many treated patients…
Complete mechanisms of renoprotective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors have not been elucidated yet…
Abstract Background There are few effective medications for non-alcoholic steatohepatitis (NASH). We investigated the efficacy of…
IntroductionEpicardial fat (EF) was reported to be independently associated with cardiovascular disease regardless of obesity. We…
ABSTRACT Objective: We recently investigated the effect of ipragliflozin, a sodium glucose co-transporter-2 inhibitor (SGLT-2I…
Background & Aims In recent years, nonalcoholic steatohepatitis (NASH) has become a considerable healthcare burden worldwide…
This multicenter, double‐blind, placebo‐controlled study examined the efficacy and safety of ipragliflozin, a sodium‐glucose co…
BACKGROUND
The sodium-dependent glucose co-transporter 2 (SGLT2) is a high-capacity, low-affinity transport system primarily…